Kato et al. found that dipeptidyl peptidase-4 inhibitor (DPP-4i), alogliptin improved coronary flow reserve in patients with T2DM and coronary artery disease [13]. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.